Mehran Afshar

674 total citations
32 papers, 258 citations indexed

About

Mehran Afshar is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Mehran Afshar has authored 32 papers receiving a total of 258 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Surgery, 14 papers in Pulmonary and Respiratory Medicine and 9 papers in Oncology. Recurrent topics in Mehran Afshar's work include Genital Health and Disease (9 papers), Renal cell carcinoma treatment (7 papers) and Urologic and reproductive health conditions (6 papers). Mehran Afshar is often cited by papers focused on Genital Health and Disease (9 papers), Renal cell carcinoma treatment (7 papers) and Urologic and reproductive health conditions (6 papers). Mehran Afshar collaborates with scholars based in United Kingdom, Norway and India. Mehran Afshar's co-authors include Nicholas D. James, Prashant Patel, Felicity Evison, Emilio Porfiri, Yuk Ting, Sarah Pirrie, Richard T. Bryan, Helen Parsons, John Parkin and Francesca Jackson‐Spence and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Journal of Hepatology.

In The Last Decade

Mehran Afshar

28 papers receiving 254 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mehran Afshar United Kingdom 10 120 116 77 40 35 32 258
Srinath Kotamarti United States 9 80 0.7× 160 1.4× 51 0.7× 18 0.5× 33 0.9× 33 262
Ioannis Zachos Greece 11 153 1.3× 137 1.2× 43 0.6× 22 0.6× 30 0.9× 43 302
Gregory T. Chesnut United States 9 70 0.6× 151 1.3× 35 0.5× 24 0.6× 23 0.7× 42 252
Nicolas Branger France 9 75 0.6× 158 1.4× 68 0.9× 25 0.6× 30 0.9× 41 265
Francesca Jackson‐Spence United Kingdom 7 121 1.0× 84 0.7× 58 0.8× 40 1.0× 31 0.9× 29 235
Breton Roussel United States 8 74 0.6× 93 0.8× 82 1.1× 19 0.5× 13 0.4× 21 327
Diana Mehedint United States 11 140 1.2× 157 1.4× 57 0.7× 28 0.7× 65 1.9× 22 317
Adnan Şimşir Türkiye 9 111 0.9× 170 1.5× 48 0.6× 18 0.5× 59 1.7× 49 322
Jacques Irani France 8 75 0.6× 216 1.9× 39 0.5× 67 1.7× 34 1.0× 12 338
In‐Chang Cho South Korea 12 121 1.0× 176 1.5× 46 0.6× 76 1.9× 48 1.4× 42 364

Countries citing papers authored by Mehran Afshar

Since Specialization
Citations

This map shows the geographic impact of Mehran Afshar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mehran Afshar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mehran Afshar more than expected).

Fields of papers citing papers by Mehran Afshar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mehran Afshar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mehran Afshar. The network helps show where Mehran Afshar may publish in the future.

Co-authorship network of co-authors of Mehran Afshar

This figure shows the co-authorship network connecting the top 25 collaborators of Mehran Afshar. A scholar is included among the top collaborators of Mehran Afshar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mehran Afshar. Mehran Afshar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bahl, Amit, Amarnath Challapalli, Balaji Venugopal, et al.. (2025). EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.. Journal of Clinical Oncology. 43(5_suppl). 1–1. 1 indexed citations
2.
Aitken, K., J Bernard, D. Timothy Bishop, et al.. (2023). Six-Month Survivorship Prediction in Spinal Metastatic Patients by Oncologists Shows Reliable Prognostication. Global Spine Journal. 15(2). 961–968.
3.
Hudda, Mohammed T, et al.. (2021). A new prognostic model for predicting 30-day mortality in acute oncology patients. Expert Review of Anticancer Therapy. 21(10). 1171–1177.
4.
5.
Patel, Reena, Alison Tree, Benjamin Ayres, et al.. (2020). Red cell differential width (RDW) as a predictor of survival outcomes with palliative and adjuvant chemotherapy for metastatic penile cancer. International Urology and Nephrology. 52(12). 2301–2306. 7 indexed citations
6.
Uemura, Mayu, et al.. (2020). Nocardia farcinica masquerading as intracerebral metastases in advanced metastatic prostatic cancer. BMJ Case Reports. 13(9). e233678–e233678. 5 indexed citations
7.
Afshar, Mehran, Hiten Patel, Maria DeSantis, et al.. (2019). Do Learning Disabilities Affect Testicular Cancer Survival: A National Cohort Study Between 2001 and 2015. European Urology Oncology. 3(6). 773–779. 7 indexed citations
8.
Afshar, Mehran, Hiten Patel, Ankit Jain, et al.. (2019). Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?. Expert Review of Anticancer Therapy. 19(6). 529–532. 4 indexed citations
9.
Corbishley, Cathy, et al.. (2019). MP49-15 SURVEILLANCE CT ALGORITHM FOR NODE POSITIVE SQUAMOUS CELL CARCINOMA OF THE PENIS. The Journal of Urology. 201(Supplement 4).
10.
Afshar, Mehran, Henry Goodfellow, Francesca Jackson‐Spence, et al.. (2017). Centralisation of radical cystectomies for bladder cancer in England, a decade on from the ‘Improving Outcomes Guidance’: the case for super centralisation. British Journal of Urology. 121(2). 217–224. 47 indexed citations
11.
Stubbs, Clive, et al.. (2017). A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib. Anticancer Research. 37(1). 253–260. 11 indexed citations
12.
Afshar, Mehran, Francesca Jackson‐Spence, Marco De Santis, et al.. (2017). Testicular cancer in patients with learning disabilities in England from 2001-2015: A national cohort study. European Urology Supplements. 16(3). e1893–e1893. 1 indexed citations
13.
Innominato, Pasquale F., Sandra Komarzynski, Ali Mohammad‐Djafari, et al.. (2016). Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project. Journal of Medical Internet Research. 18(11). e305–e305. 23 indexed citations
14.
Afshar, Mehran, Felicity Evison, Nicholas D. James, & Prashant Patel. (2015). Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience. Urologic Oncology Seminars and Original Investigations. 33(8). 338.e1–338.e7. 24 indexed citations
15.
Afshar, Mehran, Patrick Hamilton, Jenny F. Seligmann, et al.. (2015). Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?. Cancer Investigation. 33(8). 347–353. 1 indexed citations
16.
17.
Longo, Roberta, Paul D. Baxter, Peter Hall, et al.. (2014). Methods for Identifying the Cost-effective Case Definition Cut-Off for Sequential Monitoring Tests: An Extension of Phelps and Mushlin. PharmacoEconomics. 32(4). 327–334. 4 indexed citations
18.
Pirrie, Sarah, et al.. (2014). Sarcomatoid Renal Cell Carcinoma: Clinical Outcome and Survival After Treatment With Sunitinib. Clinical Genitourinary Cancer. 12(4). 251–255. 20 indexed citations
19.
20.
Afshar, Mehran, et al.. (2014). Biliary stenting in advanced malignancy: an analysis of predictive factors for survival. Cancer Management and Research. 6. 475–475. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Srinath Kotamarti Breakdown of academic impact, for papers by Ioannis Zachos Breakdown of academic impact, for papers by Gregory T. Chesnut Breakdown of academic impact, for papers by Nicolas Branger Breakdown of academic impact, for papers by Francesca Jackson‐Spence Breakdown of academic impact, for papers by Breton Roussel Breakdown of academic impact, for papers by Diana Mehedint Breakdown of academic impact, for papers by Adnan Şimşir Breakdown of academic impact, for papers by Jacques Irani Breakdown of academic impact, for papers by In‐Chang Cho
Rankless by CCL
2026